7.52
-2.72%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rockwell Medical
From its filings with the US Securities and Exchange Commission
Rockwell Medical is based in Wixom, Michigan and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RMTI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $69.3m and a net loss of $5.3m. At that date it held total assets of $57.1m and shareholders' equity of $37.0m.
Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide.
The Company is a supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment and is usually performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. This represents a large market opportunity for which we believe Rockwell's products are well-positioned to meet the needs of patients.
Rockwell manufactures hemodialysis concentrates under current Good Manufacturing Practices ("cGMP") regulations at its two facilities in Michigan and Texas and manufactures dry acid concentrate mixers at its facility in Iowa. The Company previously operated a manufacturing and warehouse facility in South Carolina, but the Company concluded manufacturing at that facility in the third quarter of 2025 as part of its ongoing efforts to streamline operations and improve efficiency.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 27 Jan 1998
- Employees
- 157
- Website
- rockwellmed.com ↗
- Head office
- 30142 WIXOM ROAD, WIXOM, MI, 48393
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Robert RadieIndependent Chairman of the Board$150,000
- Dr. Mark StrobeckPresident, Chief Executive Officer, Director, since 2022$1.3m
- Mr. Jesse NeriChief Financial Officer, Senior Vice President - Finance$539,458
- Ms. Heather HunterChief Operating Officer
- Ms. Megan TimminsExecutive Vice President, Chief Legal Officer, Secretary$749,889
- Mr. Timothy CholeSenior Vice President, Chief Commercial Officer
- Mr. Joseph DawsonDirector
- Mr. John CooperIndependent Director$137,500
- Dr. Joan LauIndependent Director$127,500
- Dr. Allen NissensonIndependent Director$127,500
- Mr. Mark RavichIndependent Director$125,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 39
- Environment
- 43
- Social
- 41
- Governance
- 34
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rockwell Medical's Triferic addresses iron deficiency in hemodialysis patients with dual formulations.
- The company targets end-stage renal disease with specialized renal drug therapies.
- Rockwell Medical's hemodialysis concentrates support dialysis providers and distributors.
Weaknesses
- The company employs 157 full-time employees, which is below industry standards.
- Rockwell Medical's focus on kidney disease limits market diversification.
- Triferic's current formulations are limited to hemodialysis applications.
Opportunities
- Expanding Triferic to chronic kidney disease segments could increase market reach.
- The US market offers growth potential for renal drug therapies.
- Developing new formulations for iron deficiency could enhance product offerings.
Threats
- Competition from established biopharmaceutical companies in Health Care sector.
- Regulatory changes could impact hemodialysis concentrate manufacturing.
- Economic downturns may reduce healthcare spending on renal therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.